A liposome-hydrogel composite delivery system significantly alleviated UVB-induced skin photoaging in mice by enhancing the stability and bioactivity of deer placenta polypeptides.

RegulatoryAugust 1, 2026

FDA Accepts Supplement for Nizoral Anti-Dandruff Application

The FDA has accepted a supplemental application for Nizoral Anti-Dandruff, containing ketoconazole.

ClinicalAugust 1, 2026

Promising Study on Serial Casting for Hypertrophic Scars in Burn Survivors

A new study aims to objectively evaluate the effects of serial casting on hypertrophic scars in adult burn survivors.

ClinicalJuly 31, 2026

Pfizer Reports Positive Phase 3 Results for LITFULO in Nonsegmental Vitiligo

LITFULO (ritlecitinib) demonstrated significant improvement in facial and total repigmentation in patients with nonsegmental vitiligo in two Phase 3 trials.

ClinicalJuly 29, 2026

Genrix initiates Phase Ib/II trial for GR2301 in vitiligo patients

Genrix is conducting Phase Ib/II trial to assess GR2301 combined with phototherapy in vitiligo patients.

RegulatoryJuly 28, 2026

FDA Submission Status Update for Calcipotriene by Glenmark

The FDA has accepted the ANDA submission for Calcipotriene by Glenmark, indicating progress in the regulatory review process.

ClinicalJuly 27, 2026

Ruxolitinib Trial for APECED-Associated Alopecia Areata Underway

A clinical trial is evaluating the efficacy and safety of ruxolitinib for hair regrowth in patients with APECED-associated alopecia areata.

CompetitiveJuly 27, 2026

Galderma R&D Evaluates Safety of Restylane Lyft for Chin Augmentation

A study is underway to assess the safety of Restylane Lyft with Lidocaine for chin augmentation after retreatment.

ClinicalJuly 27, 2026

Study on 68Ga-RGD PET-CT for Keloid Diagnosis and Treatment Evaluation

A prospective study is being conducted to assess the diagnostic value of 68Ga-RGD PET-CT in keloids.

RegulatoryJuly 26, 2026

FDA Accepts Supplement for Abreva (Docosanol) by Haleon

The FDA has accepted a supplemental application for Abreva (docosanol) submitted by Haleon.

ClinicalJuly 25, 2026

Incyte's Ruxolitinib Cream Shows Promise for Pediatric Nonsegmental Vitiligo

A clinical trial is underway to assess the safety and efficacy of ruxolitinib cream in children with nonsegmental vitiligo.

CompetitiveJuly 25, 2026

Aurobindo Pharma submits ANDA for Adapalene and Benzoyl Peroxide

Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for a combination of Adapalene and Benzoyl Peroxide.

RegulatoryJuly 25, 2026

FDA Accepts Supplement Application for Acanya by Bausch

The FDA has accepted a supplemental application for Acanya, a topical acne treatment containing benzoyl peroxide and clindamycin phosphate.

ClinicalJuly 25, 2026

Eli Lilly's LY4005130 Trial for Severe Alopecia Areata Underway

Eli Lilly is conducting a trial to evaluate the efficacy and safety of LY4005130 in adults with severe alopecia areata.

StrategyJuly 23, 2026

FDA Grants Approval for Hydrocortisone ANDA218298 by Rising

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Hydrocortisone submitted by Rising.

RegulatoryJuly 20, 2026

FDA Approves Differin Epiduo Acne Gel for Acne Treatment

The FDA has approved Differin Epiduo Acne Gel, which contains adapalene and benzoyl peroxide.

ClinicalJuly 20, 2026

Study on Crisaborole Ointment and Laser Therapy for Non-Segmental Vitiligo

A study is underway to assess the efficacy of crisaborole ointment combined with 308-nm excimer laser for treating non-segmental vitiligo.

ClinicalJuly 19, 2026

Phase 3 Study of Remibrutinib in Hidradenitis Suppurativa Underway

A Phase 3 study is assessing the efficacy, safety, and tolerability of remibrutinib in patients with moderate to severe hidradenitis suppurativa.

StrategyJuly 18, 2026

Exosomes as Promising Candidates for Dermatological and Oncological Treatments

Exosomes are identified as potential therapeutic agents for managing dermatological diseases and oncologic skin complications due to their role in intercellular communication and regulation of various biological processes.

StrategyJuly 17, 2026

FDA Grants Approval for Amneal's Tretinoin ANDA217497

The FDA has granted approval for Amneal's Abbreviated New Drug Application for Tretinoin.

ClinicalJuly 17, 2026

Ivarmacitinib shows early response linked to long-term efficacy in atopic dermatitis

A post hoc analysis of a phase-III trial indicates that early response to ivarmacitinib correlates with long-term efficacy in treating moderate-to-severe atopic dermatitis.

CompetitiveJuly 15, 2026

Benefit-risk assessment of dupilumab vs upadacitinib in atopic dermatitis

The Heads Up trial provides a structured benefit-risk assessment comparing dupilumab and upadacitinib for moderate-to-severe atopic dermatitis.

StrategyJuly 15, 2026

GDS-23 Niosomes Enhance Vitamin C Delivery and Antioxidant Uptake in Skin

GDS-23 niosomes enhance transdermal delivery of vitamin C by inducing SVCT2 and upregulating antioxidant transporters.

CompetitiveJuly 14, 2026

Dren Bio initiates Phase 1b trial of DR-01 for Alopecia Areata and Vitiligo

Dren Bio is conducting Phase 1b trial to evaluate the safety and efficacy of DR-01 in patients with Alopecia Areata and Vitiligo.

RegulatoryJuly 13, 2026

FDA Accepts Supplement Application for Brodalumab (Siliq) by Valeant

The FDA has accepted a supplemental application for Brodalumab (Siliq) submitted by Valeant Luxembourg.

ClinicalJuly 13, 2026

Phase 1 Study of BBT001 in Atopic Dermatitis Patients Initiated by Bambusa Therapeutics

Bambusa Therapeutics has initiated Phase 1 trial of BBT001 in healthy volunteers and adult patients with moderate to severe Atopic Dermatitis.

ClinicalJuly 12, 2026

Efficacy of IL-17 Inhibitors After IL-23 Failure in Psoriasis Patients

Data on the efficacy and drug survival of IL-17 inhibitors after IL-23 inhibitor failure in psoriasis patients is limited.

ClinicalJuly 12, 2026

GX03 Shows Promise in Reducing Severity of S. aureus-Induced Dermatitis in Murine Model

The study evaluates the efficacy of GX03, an extended-release topical polyhexanide formulation, in a murine model of Staphylococcus aureus-induced dermatitis.

ClinicalJuly 11, 2026

Safety Assessment of Propranolol for Infantile Hemangiomas Highlights Cardiovascular Risks

Real-world assessment of propranolol treatment for infantile hemangiomas indicates potential cardiovascular side effects.

RegulatoryJuly 11, 2026

FDA Acceptance of Supplement for Nizoral Anti-Dandruff

The FDA has accepted a supplemental application for Nizoral Anti-Dandruff, containing ketoconazole.

ClinicalJuly 10, 2026

Phase 2 Trial of HW211026 for Actinic Keratosis Initiated

A Phase 2 clinical trial has been launched to assess HW211026's efficacy and safety in adult patients with actinic keratosis.

StrategyJuly 9, 2026

FDA Grants Approval for Adapalene ANDA219565 by UNIQUE

The FDA has granted approval for ANDA219565, a generic formulation of Adapalene submitted by UNIQUE.

RegulatoryJuly 9, 2026

FDA Accepts Supplemental NDA for CIBINQO (Abrocitinib) by Pfizer

The FDA has accepted a supplemental NDA for CIBINQO (abrocitinib), indicating progress in its regulatory review.

StrategyJuly 9, 2026

Abrocitinib shows sustained disease control in atopic dermatitis post-treatment

The study evaluated off-treatment disease control in patients who received abrocitinib 200 mg for 12 weeks, showing promising results.

RegulatoryJuly 9, 2026

FDA Accepts Supplement Application for ELOCON (Mometasone Furoate)

The FDA has accepted a supplemental application for ELOCON, a topical steroid containing mometasone furoate, submitted by Organon.

RegulatoryJuly 9, 2026

LEO Pharma's Delgocitinib NDA219155 Receives AP Status from FDA

LEO Pharma's supplemental NDA for Delgocitinib has been granted an Approval Pending (AP) status by the FDA.

RegulatoryJuly 9, 2026

FDA Accepts Supplement for OPZELURA (Ruxolitinib Phosphate) by Incyte

The FDA has accepted a supplemental application for OPZELURA, an indication for Ruxolitinib Phosphate.

RegulatoryJuly 8, 2026

FDA Accepts Supplemental NDA for Sotyktu (Deucravacitinib) by Bristol

The FDA has accepted a supplemental NDA for Sotyktu (Deucravacitinib) submitted by Bristol.

RegulatoryJuly 8, 2026

FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)

The FDA has approved a supplemental NDA for Litfulo (ritlecitinib tosylate) submitted by Pfizer.

RegulatoryJuly 8, 2026

FDA Accepts Supplemental NDA for ZORYVE (Roflumilast) by Arcutis

The FDA has accepted a supplemental NDA for ZORYVE, which contains the active ingredient roflumilast.

CompetitiveJuly 8, 2026

FDA Submission Update for Azelaic Acid by Taro Pharmaceuticals

Taro Pharmaceuticals has submitted an original application for Azelaic Acid under ANDA212581.

ClinicalJuly 7, 2026

Phase 3 Study of Roflumilast Cream 0.3% Shows Promise for Plaque Psoriasis

A Phase 3 study is underway to assess the efficacy and safety of roflumilast cream 0.3% in patients with plaque psoriasis.

CompetitiveJuly 7, 2026

Chongqing Claruvis initiates study on YY001 for glabellar lines

A multi-center, open-label study is underway to assess the efficacy and safety of YY001, a recombinant botulinum toxin type A.

ClinicalJuly 6, 2026

Study on Eczema Treatments and Skin Bacteria Launches

A new clinical trial is investigating the effects of eczema treatments on skin bacteria in patients with moderate to severe atopic dermatitis.

StrategyJuly 4, 2026

FEA-guided design enhances bubble microneedles for rapid drug delivery

The study demonstrates a new design framework for bubble microneedles that improves drug delivery efficiency and speed.

RegulatoryJuly 4, 2026

FDA Acceptance of Calcipotriene Supplement by Glenmark

The FDA has accepted the supplement application ANDA205772 for Calcipotriene submitted by Glenmark.

ClinicalJuly 4, 2026

Study on Psoriasis and Cardiometabolic Disease Relationship Launched by NHLBI

The NHLBI has initiated a study to explore the relationship between psoriasis and cardiometabolic diseases.

ClinicalJuly 4, 2026

Study on Risk Stratification in Infantile Hemangioma With Minimal Growth Initiated

A prospective observational study is underway to evaluate management strategies for infants with IH-MAG compared to classic hemangiomas.

ClinicalJuly 3, 2026

Sun Pharma initiates trial for deuruxolitinib in severe alopecia areata in Japan

A clinical trial is underway to assess deuruxolitinib's efficacy and safety in Japanese adults with severe alopecia areata.

RegulatoryJuly 3, 2026

FDA Accepts Supplemental Application for ABREVA by Haleon

The FDA has accepted a supplemental application for ABREVA, a cold sore treatment containing docosanol.

ClinicalJuly 3, 2026

Apogee Therapeutics initiates long-term safety study for APG777 in atopic dermatitis

Apogee Therapeutics is conducting a long-term safety and efficacy study for APG777 in patients with moderate-to-severe atopic dermatitis.

ClinicalJuly 2, 2026

Clinical Trial on Ultrasound and TCM for Keloid Treatment Shows Promising Results

A clinical trial is underway to evaluate the safety and efficacy of wide-band ultrasound combined with TCM for keloid treatment, showing promising preliminary results.

RegulatoryJuly 1, 2026

Glenmark Pharmaceuticals receives FDA acceptance for Ciclopirox ANDA090273

The FDA has accepted Glenmark Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Ciclopirox.

RegulatoryJuly 1, 2026

Apotex submits supplemental ANDA for Imiquimod

Apotex Inc. has submitted a supplemental Abbreviated New Drug Application (ANDA091308) for Imiquimod.

RegulatoryJuly 1, 2026

FDA Approves Fluocinolone Acetonide Supplement by Sun Pharma

The FDA has approved a supplemental application for Fluocinolone Acetonide submitted by Sun Pharma.

ClinicalJune 29, 2026

Scotiaderm Initiates Trial for Novel Barrier Cream Against Moisture Associated Skin Damage

Scotiaderm is conducting a clinical trial to evaluate the efficacy of its Dermategrity 'Anti-fecal' Barrier Cream against standard zinc oxide creams for treating moisture-associated skin damage.

CompetitiveJune 28, 2026

AbbVie Evaluates AGN-151586 with BOTOX for Glabellar Lines in New Trial

A new clinical trial is assessing the safety and efficacy of AGN-151586 in combination with BOTOX for treating glabellar lines.

CompetitiveJune 26, 2026

AbbVie Trials Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Dupilumab Inadequate Responders

A new clinical trial is evaluating upadacitinib in adults with moderate-to-severe atopic dermatitis who have not responded adequately to dupilumab.

ClinicalJune 26, 2026

Janssen's Guselkumab Trial Targets Skin of Color Patients with Psoriasis

A clinical trial is underway to assess the efficacy of guselkumab in skin of color participants with moderate-to-severe psoriasis.

ClinicalJune 24, 2026

Phase III Trial of MC2-01 Cream for Plaque Psoriasis Shows Efficacy and Safety

A Phase III trial is underway to evaluate the efficacy and safety of MC2-01 cream compared to existing treatments in plaque psoriasis.

RegulatoryJune 23, 2026

FDA Approval Status Update for Isotretinoin by Upsher Smith Labs

The FDA has granted an Approval Pending (AP) status for the isotretinoin application ANDA213571 submitted by Upsher Smith Labs.

CompetitiveJune 23, 2026

Mastelli S.r.l. initiates study on PN+HA for skin hydration improvement

A post-market clinical investigation is underway to evaluate the efficacy and safety of PN+HA for skin hydration.

ClinicalJune 22, 2026

Deucravacitinib shows promise in Pityriasis Rubra Pilaris study by Mayo Clinic

A study is underway to evaluate the safety and effectiveness of Deucravacitinib in patients with Pityriasis Rubra Pilaris.

ClinicalJune 22, 2026

Boehringer Ingelheim Initiates Long-term Study of Spesolimab for Hidradenitis Suppurativa

Boehringer Ingelheim is conducting a long-term study to evaluate the tolerance and efficacy of spesolimab in patients with hidradenitis suppurativa.

ClinicalJune 20, 2026

Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults

A study is underway to evaluate the efficacy and safety of dupilumab in treating bullous pemphigoid, an autoimmune blistering disease.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for Absorica by Sun Pharma

The FDA has accepted a supplemental application for Absorica, an isotretinoin product from Sun Pharma.

ClinicalJune 20, 2026

First-in-Human Study of BGB-45035 in Healthy Adults and Autoimmune Patients

The first-in-human study of BGB-45035 will assess its safety and pharmacokinetics in healthy participants and adults with autoimmune dermatological diseases.

ClinicalJune 19, 2026

Teva's TEV-53408 Trial for Vitiligo Focuses on Safety and Efficacy

Teva is conducting a trial to assess the safety and efficacy of TEV-53408 in adults with vitiligo over an 84-week period.

RegulatoryJune 18, 2026

FDA Accepts Supplement for ABSORICA LD by Sun Pharma

The FDA has accepted a supplemental application for ABSORICA LD, an isotretinoin product by Sun Pharma.

StrategyJune 18, 2026

FDA Grants Approval for Tretinoin ANDA214590 by Alembic

The FDA has granted approval for Alembic's Abbreviated New Drug Application (ANDA) for Tretinoin.

RegulatoryJune 17, 2026

FDA Lists Quinacrine Hydrochloride for Compounding in Cutaneous Lupus Erythematosus

Quinacrine is included on the FDA 503B list for compounding, indicating a clinical need for its use in treating cutaneous lupus erythematosus.

ClinicalJune 17, 2026

Phase I/II Trial of Adipose-derived Stem Cells for Burn Scarring Initiated in Denmark

A phase I/II trial (ScarASC) is underway to evaluate the efficacy of allogeneic adipose-derived stem cells for treating hypertrophic scars in burn survivors.

RegulatoryJune 16, 2026

FDA approves Lilly's EBGLYSS® for atopic dermatitis with unique dosing regimen

Lilly's EBGLYSS® (lebrikizumab-lbkz) is now approved for a maintenance dose every eight weeks, requiring only six injections per year.

CompetitiveJune 13, 2026

Phase 3 Study of CU-20101 Shows Promise for Glabellar Lines Compared to Botox

A Phase 3 clinical study is underway to assess CU-20101's efficacy and safety against Botox for glabellar lines.

ClinicalJune 12, 2026

Trial Compares Silicone Barrier Spray to Zinc Oxide for Incontinence-Associated Dermatitis

A randomized controlled trial is evaluating the effectiveness of silicone barrier spray versus zinc oxide ointment for mild incontinence-associated dermatitis.

Upcoming catalysts(1)

Label Expansion

Incyte — Opzelura

Pediatric vitiligo label would deepen JAK inhibitor franchise in dermatology.

September 5, 2026 · Approved

Indications

Autoimmune Disease →

Autoimmune Diseases →

Autoimmune Disorders →

Psoriasis →

Psoriasis and Eczema →

Skin Disorders →

Vitiligo (pediatric) →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.